stoxline Quote Chart Rank Option Currency Glossary
  
IMV Inc. (IMV)
0.8225  0 (0%)    04-28 15:58
Open: 0.811
High: 0.84
Volume: 44,894
  
Pre. Close: 0.8225
Low: 0.7753
Market Cap: 10(M)
Technical analysis
2023-07-07 4:46:40 PM
Short term     
Mid term     
Targets 6-month :  0.33 1-year :  0.53
Resists First :  0.28 Second :  0.45
Pivot price 0.09
Supports First :  0 Second :  0
MAs MA(5) :  0.1 MA(20) :  0.1
MA(100) :  0.73 MA(250) :  3.04
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  15.7 D(3) :  23.6
RSI RSI(14): 38.5
52-week High :  10.39 Low :  0
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ IMV ] has closed above bottom band by 42.7%. Bollinger Bands are 90.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.1 - 0.1 0.1 - 0.1
Low: 0.08 - 0.08 0.08 - 0.08
Close: 0.09 - 0.09 0.09 - 0.09
Company Description

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Headline News

Tue, 26 Mar 2024
IMV INC (IMV) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Movies Canada

Tue, 26 Mar 2024
IMV (TSE:IMV) Shares Down 1.8% - Defense World

Wed, 21 Feb 2024
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS ... - PR Newswire

Thu, 15 Feb 2024
BioVaxys Acquires Full Portfolio of Former IMV - Pharmaceutical Technology Magazine

Tue, 13 Feb 2024
BioVaxys snatches up 'bankrupt' IMV's preclinical and clinical assets - Pharmaceutical Technology

Mon, 12 Feb 2024
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the ... - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 12 (M)
Held by Insiders 1.017e+007 (%)
Held by Institutions 0.4 (%)
Shares Short 31 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.958e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -12 %
Return on Assets (ttm) 239.2 %
Return on Equity (ttm) -61.8 %
Qtrly Rev. Growth 329000 %
Gross Profit (p.s.) 49.34
Sales Per Share -334.6
EBITDA (p.s.) -1.53158e+007
Qtrly Earnings Growth -4.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -33 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow -0.2
Stock Dividends
Dividend 0
Forward Dividend 311110
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android